查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197821

眼科药物和设备市场 - 增长、趋势和预测 (2023-2028)

Ophthalmology Drug and Device Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 125 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，眼科药品和设备市场预计将以 5.5% 的复合年增长率註册。

COVID-19 大流行最初对市场产生了重大影响，因为一些国家被封锁并且与其他国家的贸易由于旅行限製而停止，导致眼科诊断下降。 疫情期间，不少眼科医生出于警惕，暂时停业。 根据《印度眼科杂誌》2021 年 12 月发表的一篇文章，一项针对全印度眼科学会 (AIOS) 成员的调查显示，COVID-19 对全印度的眼科保健服务产生了负面影响。 随着 COVID-19 病例数量大幅下降，市场开始復苏并获得牵引力。 因此，预计在本研究的预测期内，市场将稳步增长。

推动市场增长的某些因素包括眼科疾病流行的影响、人口结构变化、眼科领域的技术进步以及老年人口的增加。 根据世界卫生组织2022年10月更新的数据，估计全球至少有22亿人患有近视或远视。 其中，至少有 10 亿人已经预防或尚未解决视力丧失问题。 在这 10 亿人中，有未解决的屈光不正（8840 万）、白内障（9400 万）、年龄相关性黄斑变性（800 万）、青光眼（770 万）和糖尿病性视网膜病变（390 万）。这包括中度或重度远视力障碍和因各种疾病（例如人类疾病）导致的失明），以及因未经治疗的老花眼导致的近视力障碍（826 万人）。 在许多国家，白内障手术是最常进行的外科手术，能够以低成本显着改善老年人的生活质量。 老年人口的增长和眼科疾病的高患病率正在增加对眼科设备的需求，并预见到未来的白内障手术需求对人力资源、医院和手术中心的管理和规划至关重要。 其他因素，如新设备和新药的出现，以及眼科疾病发病率的增加，预计也将在预测期内推动市场。

此外，主要市场参与者的新产品发布和战略活动对所研究市场的增长产生了积极影响。 例如，2022 年 6 月，Biogen Inc. 和 Samsung Bioepis 在美国推出了 ranibizumab nuna（Bjobiz，Biogen），这是一种参考雷珠单抗（Lucentis，Genentech）的眼科生物仿製药。 因此，由于产品发布和合作伙伴关係，预计所研究的市场在预测期内将显着增长。

因此，由于上述因素，预计所研究的市场在分析期内会出现增长。 然而，眼科设备和治疗成本的上升，以及 FDA 对药物批准的严格指导方针，可能会阻碍市场增长。

眼科药物和设备的市场趋势

预计青光眼细分市场在预测期内将出现显着增长

青光眼是视力丧失和失明的最常见原因之一。 由于青光眼是一种不可逆转的疾病，因此早期发现和治疗至关重要。 随着人口老龄化，青光眼的发病率预计将很快上升，成为市场增长的推动力。

根据印度政府 MoHFW 发布的数据，到 2021 年 3 月，青光眼将成为全球第二大失明原因，WHO 估计有 450 万人因青光眼而失明。 . 此外，数据显示，青光眼是印度不可逆转失明的第一大原因，影响至少 1200 万人，约 120 万人因该病失明。 据估计，超过 90% 的青光眼患者在其社区中未被确诊。 青光眼的高患病率预计将推动未来几年的市场增长。

在欧洲，核性开角型青光眼造成了重大的公共卫生负担，在不久的将来对该设备的需求可能会增加。 例如，根据 2022 年 8 月发表在 ScienceDirect 上的一篇文章，大多数青光眼患者应该定期进行积极监测和管理，以防止不可逆转的视力丧失。 该论文进一步指出，青光眼的治疗目前估计占英国医院眼科服务门诊工作量的 20%，每年有超过 100 万与青光眼相关的英国医院眼科就诊。他说患者正在就诊。 由于人口老龄化、获得视力测试的机会增加以及眼科检查（包括视网膜成像）的严格程度提高，预计与青光眼相关的门诊就诊人数将会增加。

此外，根据 2022 年 5 月发表在 Journal of Ophthalmology 上的一篇研究论文，青光眼是最常见的威胁视力的眼病之一。 它通常伴有眼内压 (IOP) 过高，眼睛（视）神经的衰竭可导致视力丧失甚至失明。 此外，由于青光眼是一种主要影响老年人的疾病，预计由于老年人口增加等因素，患者人数也会增加。

因此，青光眼的高发病率将增加对药品和器械的需求，预计在预测期内将出现大幅增长。

预计在预测期内北美将占据很大的市场份额

由于完善的医疗保健设施、不断增长的老年人口以及大公司的存在，预计北美地区将出现显着增长。 由于美国老年人口不断增加、视力矫正的趋势及其在重要人群中的使用，美国大多数类型眼镜的销售率都有所提高。 美国在北美的眼科诊断设备市场占有很大份额。 随着人口老龄化的迅速增长以及由于高压力和不健康的生活方式导致的眼病患病率上升可能导致糖尿病视网膜病变等疾病，市场预计将增长。 人口老龄化加剧，更易患眼疾，市场增长基数有望进一步扩大。

青光眼、白内障、黄斑变性和糖尿病性视网膜病变等眼科疾病的患病率正在上升，预计将在预测期内推动市场。 根据青光眼研究基金会 2022 年 2 月的数据，估计有超过 300 万美国人患有青光眼。 然而，只有一半的人知道这种疾病。 美国有超过12万人因青光眼失明，占所有失明人数的9%至12%。 因此，眼科疾病的增加将导致对药品和设备的需求增加。

大量产品发布、市场参与者高度集中或製造商在美国的存在是推动所研究的该国市场增长的一些因素。 例如，2022年4月，山德士推出仿製药复方滴眼液，酒石酸溴莫尼定/马来酸塞吗洛尔滴眼液0.2%/0.5%。 它是 AbbVie 的 Comvigan 的 AB 级仿製药，可降低美国高眼压症（高眼压症）患者的眼内压。 此外，2021 年 12 月，Allergan推出了 VUITY（盐酸毛果芸香碱滴眼液 1.25%），这是美国 FDA 批准的第一个也是唯一一个治疗老花眼的滴眼液。 这些持续推出的产品预计将推动该地区的市场增长。

因此，由于上述因素，北美地区的市场有望增长。

眼科药品和器械市场的竞争对手分析

眼科药物和设备市场较为分散。 竞争格局包括对少数具有市场份额的知名国际和本地公司的分析。 它由 Alcon Inc.、Bausch Health Companies Inc.、Carl Zeiss Meditec AG、Essilor International SA、Haag-Streit Group (Metall Zug AG)、Johnson & Johnson、Nidek、Topcon Corporation 和 Ziemer Group AG 等主要公司组成。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 人口结构的变化及其对眼科疾病患病率的影响
    • 眼科领域的技术进步
  • 市场製约因素
    • 眼科设备和治疗费用高昂
    • 严格的 FDA 药物审批指南
  • 波特的五力分析
    • 供应商的议价能力
    • 买方/消费者议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按产品分类
    • 设备
      • 手术器械
      • 人工晶状体
      • 眼科激光
      • 其他手术设备
      • 诊断设备
    • 药物
      • 青光眼药物
      • 视网膜疾病的治疗
      • 干眼症治疗
      • 过敏性结膜炎/炎症药物
      • 其他药物
  • 按疾病分类
    • 青光眼
    • 白内障
    • 年龄相关性黄斑变性
    • 炎症性疾病
    • 屈光矫正
    • 其他疾病
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Alcon Inc.
    • Bausch Health Companies Inc.
    • Carl Zeiss Meditec AG
    • Essilor International SA
    • Haag-Streit Group（Metall Zug AG）
    • Johnson & Johnson
    • Nidek Co. Ltd
    • Topcon Corporation
    • NIDEK Co. Ltd
    • Lumenis Ltd
    • Ziemer Ophthalmic Systems AG

第第七章市场机会与未来趋势

简介目录
Product Code: 48323

The ophthalmology drug and device market is expected to witness a CAGR of 5.5% during the forecast period.

The COVID-19 pandemic had a significant impact on the market initially as several countries were in lockdown, and trades were suspended with other countries with travel restrictions, leading to a decline in eye diagnoses. As a cautionary measure, many ophthalmologists temporarily closed their practices during the pandemic. According to an article published by the Indian Journal of Ophthalmology in December 2021, a survey was conducted among the All India Ophthalmological Society (AIOS) members, which stated that COVID-19 had adversely affected ophthalmic care services across the whole of India. As the number of COVID-19 cases has decreased significantly, the market has recovered and started to gain traction. Hence, the market is expected to have stable growth during the forecast period of the study.

Certain factors driving the market's growth include the impact of the prevalence of eye disease, demographic shift, technological advancements in the field of ophthalmology, and the rising geriatric population. According to the data updated by WHO in October 2022, it is estimated at least 2.2 billion people will have a near or distant vision impairment globally. Among these, at least 1 billion people's vision impairment could have been prevented or yet to get addressed. These 1 billion people include those with moderate or severe distance vision impairment or blindness due to various diseases like unaddressed refractive error (88.4 million), cataract (94 million), age-related macular degeneration (8 million), glaucoma (7.7 million), diabetic retinopathy (3.9 million), as well as near vision impairment caused by unaddressed presbyopia (826 million). In many countries, cataract surgery is the most common surgical procedure performed, significantly improving the quality of life of the elderly population at low costs. An increase in the elderly population and the high prevalence of ophthalmic disorders increases the demand for ophthalmological devices and projects the future cataract surgery needs vital for human health resources, hospitals, and surgical centre management and planning. Other factors, such as the availability of new devices and new drugs and the growing incidence of eye disease, are also expected to drive the market over the forecast period.

In addition, new product launches and strategic activities by major players in the market are positively affecting the growth of the studied market. For example, in June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. launched ranibizumab-nuna (Byooviz, Biogen), an ophthalmic biosimilar referencing ranibizumab (Lucentis, Genentech) in the US. Thus, due to the product launches and partnerships, the studied market is expected to grow significantly over the forecast period.

Therefore, owing to the factors above, the studied market is anticipated to witness growth over the analysis period. However, the higher cost of ophthalmic devices and treatment and strict FDA guidelines for drug approval is likely to impede the market's growth.

Ophthalmology Drug & Device Market Trends

The Glaucoma Segment is Expected to Show Significant Growth in the Forecast Years

Globally, glaucoma is one of the most common causes of vision loss or blindness. Being irreversible, the early detection and management of glaucoma are of utmost importance. With increasing ageing, the incidence of glaucoma is expected to rise shortly, driving market growth.

According to the data published by the MoHFW, Government of India, in March 2021, glaucoma is estimated to be the second most common cause of blindness worldwide, and WHO estimated that 4.5 million people are blind due to glaucoma. The data further revealed that in India, glaucoma is the leading cause of irreversible blindness, with a minimum of 12 million people affected and nearly 1.2 million people blind from the disease. It is also estimated that more than 90% of glaucoma cases are undiagnosed in the community. With the high prevalence of glaucoma, it is expected to drive market growth in the coming years.

Primary open-angle glaucoma is a significant public health burden in Europe, likely increasing the demand for devices soon. For instance, as per an article published by ScienceDirect in August 2022, most individuals affected with glaucoma require regular active monitoring and management to prevent irreversible vision loss. The article further states glaucoma care currently accounts for an estimated 20% workload of hospital eye service outpatients in the UK, with over 1 million glaucoma-related outpatient visits made each year to hospital eye services in England. With an ageing population, increased access to sight testing, and more rigorous optometry screening (including retinal imaging), the number of glaucoma-related outpatient visits is expected to rise.

Furthermore, according to a research article published by the Journal of Ophthalmology in May 2022, glaucoma is considered one of the most frequent vision-threatening eye diseases. It is frequently associated with excessive Intraocular Pressure (IOP) that causes vision loss and possibly blindness if the eye's (optic) nerve fails. Factors such as the increasing geriatric population are also expected to increase the number of glaucoma patients as the disorder primarily affects older people.

Thus, the high incidence of glaucoma is expected to raise demand for drugs and devices and show significant growth over the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

Due to the presence of well-established healthcare facilities, the rise in the geriatric population in the region, and the presence of large companies, the North American region is expected to grow significantly. Due to the constant increase in the American elderly population, a move toward vision correction and its usage among crucial demographics, an increase in rates for most eyewear types was observed in the US. The United States holds a substantial share of the ophthalmology diagnostics market in the North American region. The market is expected to grow due to the rapidly increasing geriatric population and the rising prevalence of eye diseases due to high stress and unhealthy lifestyles, which can result in conditions such as diabetic retinopathy. The geriatric population is increasing, and it is more susceptible to developing eye diseases, which is further anticipated to widen the base for market growth.

There has been a rising prevalence of eye diseases, such as glaucoma, cataract, macular degeneration, and diabetic retinopathy, which is anticipated to propel the market over the forecast period. As per the data by the Glaucome Research Foundation in February 2022, it is estimated that over 3 million Americans have glaucoma. Still, only half of those are aware of the disease. In the United States, more than 120,000 are blind from glaucoma, accounting for 9% to 12% of all cases of blindness. Hence, an increase in eye disorders will lead to a growing demand for drugs and devices.

Key product launches, high concentration of market players, or manufacturers' presence in the United States are some factors driving the studied market growth in the country. For instance, in April 2022, Sandoz launched its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%. It is an AB-rated generic equivalent to AbbVie's COMBIGAN to lower eye pressure in patients with ocular hypertension (high eye pressure) in the United States. Furthermore, in December 2021, Allergan launched VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the US FDA to treat presbyopia. These continuous product launches in the region are anticipated to drive market growth in the country.

Therefore, owing to the factors above, the growth of the studied market is anticipated in the North American region.

Ophthalmology Drug & Device Market Competitor Analysis

The ophthalmology drug and device market are moderately fragmented in nature. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. It consists of major players such as Alcon Inc., Bausch Health Companies Inc., Carl Zeiss Meditec AG, Essilor International SA, Haag-Streit Group (Metall Zug AG), Johnson & Johnson, Nidek Co. Ltd, Topcon Corporation, Ziemer Group AG, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Demographic Shift and Impact of Prevalence of Eye Disease
    • 4.2.2 Technological Advancements in the Field of Ophthalmology
  • 4.3 Market Restraints
    • 4.3.1 Higher Cost of the Ophthalmic Devices and Treatment
    • 4.3.2 Strict FDA Guidelines for Drug Approval
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Devices
      • 5.1.1.1 Surgical Devices
      • 5.1.1.1.1 Intraocular Lenses
      • 5.1.1.1.2 Ophthalmic Lasers
      • 5.1.1.1.3 Other Surgical Devices
      • 5.1.1.2 Diagnostic Devices
    • 5.1.2 Drugs
      • 5.1.2.1 Glaucoma Drugs
      • 5.1.2.2 Retinal Disorder Drugs
      • 5.1.2.3 Dry Eye Drugs
      • 5.1.2.4 Allergic Conjunctivitis and Inflammation Drugs
      • 5.1.2.5 Other Drugs
  • 5.2 By Disease
    • 5.2.1 Glaucoma
    • 5.2.2 Cataract
    • 5.2.3 Age-Related Macular Degeneration
    • 5.2.4 Inflammatory Diseases
    • 5.2.5 Refractive Disorders
    • 5.2.6 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alcon Inc.
    • 6.1.2 Bausch Health Companies Inc.
    • 6.1.3 Carl Zeiss Meditec AG
    • 6.1.4 Essilor International SA
    • 6.1.5 Haag-Streit Group (Metall Zug AG)
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Nidek Co. Ltd
    • 6.1.8 Topcon Corporation
    • 6.1.9 NIDEK Co. Ltd
    • 6.1.10 Lumenis Ltd
    • 6.1.11 Ziemer Ophthalmic Systems AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS